<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119518</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00614</org_study_id>
    <nct_id>NCT04119518</nct_id>
  </id_info>
  <brief_title>Night Ambulatory Monitoring Of Blood Pressure</brief_title>
  <acronym>NAMBP</acronym>
  <official_title>Night Ambulatory Monitoring Of Blood Pressure Clinical Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine accuracy of nightly non occlusive blood pressure measurements by the&#xD;
      non-occlusive CSEM Pulse Watch compared to a gold standard oscillometric device Spacelabs&#xD;
      OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA)&#xD;
      internationally validated for the 24h ABPM in Patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Elevated Blood Pressure (BP) is a chronic medical condition with a prevalence of about 45% in&#xD;
      the middle-aged population.&#xD;
&#xD;
      The particular interest of this project is given to the diagnosis and treatment of so-called&#xD;
      nocturnal hypertension. Unfortunately, current monitoring practice relies on the use of&#xD;
      occlusive pneumatic cuffs inflated around the arm to assess BP. Based on oscillometric&#xD;
      technique, occlusive cuffs perform intermittent BP measurements every 20 minutes, thus&#xD;
      providing only a limited view of the BP regulation landscape. In addition, oscillometric&#xD;
      measurement performs a full occlusion of the measured arm inducing awakening reactions, and&#xD;
      leading to non-representative overestimated BP values. The non-occlusive measurement of BP is&#xD;
      thus an unsolved problem of modern medicine.&#xD;
&#xD;
      The aim of the NAMBP (Night Ambulatory Monitoring of Blood Pressure) project is to develop,&#xD;
      implement and test in clinical trials a first-ever non-occlusive BP sensor to be used during&#xD;
      sleep.&#xD;
&#xD;
      A novel technology for the non-occlusive measurement of BP from photoplethysmographic&#xD;
      (optical) signals, known as Pulse Wave Analysis (PWA), has been investigated for the past&#xD;
      decade by the Centre Suisse d'Electronique et de Microtechnique (CSEM, Neuchâtel,&#xD;
      Switzerland). The herein proposed system - the CSEM Pulse Watch - consists in a single sensor&#xD;
      (watch-like device) attached at the wrist that measures photoplethysmographic waveforms&#xD;
      induced by the pulsatility of the skin arteries of the wrist. These waveforms are then&#xD;
      post-processed via PWA: The system will detect features in the measured waveforms that&#xD;
      correlate, through the phenomenon of wave reflections, to the underlying BP of the patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, method-comparison, proof of concept, single centre study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the accuracy</measure>
    <time_frame>Day 0 for 24 hours</time_frame>
    <description>Continuous blood pressure measurement of the novel device will be compared to measurements assessed by a standard 24h blood pressure monitor at normal out of hospital conditions during night periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the acceptability</measure>
    <time_frame>Day 1</time_frame>
    <description>Acceptability of the novel blood pressure device in patients when used during 24 hours will be assessed by means of a questionnaire filled in by patients at day 1. The scale title is: Fragebogen. The minimum value is -1 and the maximum value is 10. The higher score means worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Healthy and hypertensive subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be enrolled to be monitored for 24 hours via: the non-occlusive CSEM Pulse Watch, and a gold standard oscillometric device (Spacelabs OnTrak Ambulatory Blood Pressure monitor, Spacelabs Healthcare, Washington, USA) internationally validated for the 24h ABPM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CSEM Pulse Watch</intervention_name>
    <description>Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.</description>
    <arm_group_label>Healthy and hypertensive subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18y&#xD;
&#xD;
          -  Good understanding of written and oral German&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Scheduled for 24h blood pressure exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unhealthy mental state&#xD;
&#xD;
          -  Patients with an active implantable medical device (AIMD)&#xD;
&#xD;
          -  Arteriopathy of the upper limbs with/without stenosis&#xD;
&#xD;
          -  Severe congestive heart failure (LV-EF ≤25%)&#xD;
&#xD;
          -  Sever aortic-valve stenosis mean gradient &gt;40mmHg, valve area &lt;1cm2)&#xD;
&#xD;
          -  Congenital heart disease including aortic isthmus stenosis&#xD;
&#xD;
          -  Untreated heart rhythm disorders, heart rate at rest &gt; 120/bpm&#xD;
&#xD;
          -  Severe untreated arterial hypertension (BPsyst &gt; 180mmHg, BPdiast &gt; 100mmHg)&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Instable angina pectoris&#xD;
&#xD;
          -  Malcompliance concerning medication intake&#xD;
&#xD;
          -  Active alcohol or drug abuse&#xD;
&#xD;
          -  Pregnancy or lactation (women of childbearing age will be asked to performed urinary&#xD;
             pregnancy test before the screening phase)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emrush Rexhaj, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Inselspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emrush Rexhaj, MD</last_name>
    <phone>+41316322111</phone>
    <phone_ext>+41316322111</phone_ext>
    <email>emrush.rexhaj@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emrush Rexhaj</last_name>
    <phone>+41316322111</phone>
    <phone_ext>+41316322111</phone_ext>
    <email>emrush.rexhaj@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emrush Rexhaj, MD</last_name>
      <phone>+41316322111</phone>
      <email>emrush.rexhaj@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jeremias Ambühl, MD</last_name>
      <phone>+41316322111</phone>
      <email>jeremias.ambuehl@students.unibe.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

